What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. In research literature it is commonly described as a selective agonist of the growth hormone secretagogue receptor pathway, often abbreviated as GHSR or GHS-R1a. Its primary research interest is the way it can stimulate growth hormone release in experimental models while showing a more selective endocrine profile than older GHRP compounds.
The sequence is usually described as Aib-His-D-2-Nal-D-Phe-Lys-NH2. Product specifications can vary depending on salt form and analytical method, so the individual product listing should always be treated as the source of truth for molecular weight, quantity, storage details, and batch information.
Why Ipamorelin Is Discussed in GH-Release Research
Ipamorelin became notable because early pharmacology work described it as the first selective growth hormone secretagogue. The compound was compared with other GHRP-type molecules in pituitary and animal models, with the key point being selectivity: the study reported GH release without the same ACTH and cortisol response seen with GHRP-2 or GHRP-6 in that model.
That selectivity is the reason Ipamorelin is often discussed in growth hormone axis research. It gives researchers a way to examine GHSR-mediated GH release while reducing some of the confounding endocrine activity associated with less selective secretagogues.
Research Mechanism and Receptor Context
Ipamorelin is generally placed in the growth hormone secretagogue peptide family. These compounds are studied because they interact with receptor systems involved in pituitary GH release rather than acting as growth hormone itself.
- Target pathway: growth hormone secretagogue receptor signalling, commonly discussed as GHSR-1a.
- Primary research readout: GH release and downstream GH/IGF-1 axis markers in controlled experimental contexts.
- Selectivity point: interest comes from limited ACTH/cortisol response in the original comparative research model.
- Common comparison group: GHRP-2, GHRP-6, sermorelin, GHRH analogues, and CJC-1295 variants.
Ipamorelin vs CJC-1295 in Research Discussions
Ipamorelin and CJC-1295 are often mentioned together, but they are not the same type of molecule. Ipamorelin is a GHSR agonist, while CJC-1295 is a GHRH analogue. That means they are commonly discussed as complementary GH-axis research tools because they relate to different receptor pathways.
In simple terms, Ipamorelin research is usually framed around growth hormone secretagogue receptor activity. CJC-1295 research is framed around growth hormone-releasing hormone receptor activity. The distinction matters because comparing these categories helps keep product-page language and research planning more precise.
Product Listing and Handling Notes
When comparing catalogue entries, check the strength, vial quantity, product title, and any batch-specific information before adding to basket. PeptidesNextDay currently lists Ipamorelin 2mg and Ipamorelin 5mg, with product pages used for the latest stock, price, and handling details.
Lyophilised peptide products should be reviewed alongside the site storage guide, reconstitution guide, and product-page notes. The blog is intended to support terminology and product comparison only; it does not provide dosing, administration, clinical, diagnostic, or therapeutic guidance.
Research Use Notice
Ipamorelin products sold through PeptidesNextDay are specialist peptide products. They are not medicines or supplements and are not approved for human or veterinary administration. Customers should use the product page, checkout information, and support channels for order-specific questions.